Ποια είναι η τιμή για ProMIS Neurosciences, Inc. (PMN)

Η τιμή για ProMIS Neurosciences, Inc. (PMN) είναι $4.40

Ποια είναι η κεφαλαιοποίηση αγοράς για ProMIS Neurosciences, Inc. (PMN)

Η κεφαλαιοποίηση αγοράς για ProMIS Neurosciences, Inc. (PMN) είναι $37.78M

ProMIS Neurosciences, Inc. (PMN) Τιμή και Κεφαλαιοποίηση Αγοράς

Based in Toronto, Canada, ProMIS Neurosciences, Inc. focuses on developing precise medical solutions for severe neurodegenerative disorders, including Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company employs a unique discovery platform, which incorporates proprietary algorithms like ProMIS and Collective Coordinates, to identify novel, disease-specific targets, known as epitopes, located on the surface of misfolded proteins. The firm's primary product candidates include PMN310, a monoclonal antibody designed to combat toxic oligomers associated with Alzheimer's disease. Another candidate, PMN267, aims to target proteins such as superoxide dismutase 1 and TAR-DNA binding protein 43 relevant to ALS, as well as alpha-synuclein implicated in Parkinson's disease and Lewy body dementia. Additionally, PMN442 is a monoclonal antibody engineered to address toxic alpha-synuclein oligomers and seeding fibrils linked to MSA. Originally established in 2004, the company was known as Amorfix Life Sciences Ltd. before officially adopting the name ProMIS Neurosciences, Inc. in July 2015.

Η τιμή για PMN	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$617,828 $37.78M	NVDA	$5.301T	+14,029,909.56%
$540,088 $37.78M	AAPL	$4.634T	+12,264,535.48%
$482,874 $37.78M	GOOG	$4.143T	+10,965,285.33%
$418,350 $37.78M	MSFT	$3.589T	+9,500,029.84%
$332,984 $37.78M	AMZN	$2.857T	+7,561,494.96%

Η τιμή για PMN

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$617,828 $37.78M